---
title: "Moderna and Merck’s cancer vaccine algorithm: what’s known and why it matters"
id: "stat-news-1-what-s-in-merck-and-moderna-s-cancer-vaccine-algorithm"
canonical_url: "https://medichelpline.com/clinical-feed/stat-news-1-what-s-in-merck-and-moderna-s-cancer-vaccine-algorithm"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "STAT News"
source_url: "https://www.statnews.com/2026/08/27/biotech-news-whats-in-merck-and-modernas-cancer-vaccine-algorithm/?utm_campaign=rss"
published_at: "2026-08-27T14:49:21.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Moderna and Merck’s cancer vaccine algorithm: what’s known and why it matters
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/stat-news-1-what-s-in-merck-and-moderna-s-cancer-vaccine-algorithm
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** STAT News
- **Source URL:** [Original Journal Publication](https://www.statnews.com/2026/08/27/biotech-news-whats-in-merck-and-modernas-cancer-vaccine-algorithm/?utm_campaign=rss)
- **Published At:** 2026-08-27T14:49:21.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- Moderna and Merck reported Phase 3 success with a **personalized cancer vaccine** that uses software to analyze tumor mutations and select 34 neoantigens to encode into a bespoke mRNA vaccine for each patient. The companies are raising debate about whether the algorithm is the key driver of efficacy or if mRNA primes tumors generally. - Moderna is pursuing roughly **$2 billion** in convertible debt weeks after the vaccine’s Phase 3 success, underscoring commercial momentum and investor interest tied to the program. - Some Wall Street skeptics question whether personalization is essential, suggesting that mRNA delivery itself may enhance responses to checkpoint blockade such as **Keytruda**. - Cancer vaccine algorithm details are proprietary and opaque; experts like Alex Rubinsteyn say they do not know the algorithm’s specifics and companies claim their approaches are proprietary intelligence. - A separate U.S. bipartisan bill, the Biotech Investment National Security Act (**BINSA**), would limit U.S.–China biotech ties and could shift development and licensing activity to Europe via so-called “Eurowashing,” potentially benefiting European sponsors and trial sites. - In cardiology-related biotech news, AstraZeneca and Ionis reported that their gene-silencing drug eplontersen failed a pivotal Phase 3 cardiovascular endpoint, raising questions about the added benefit of injectable gene silencers versus oral stabilizer drugs; this has implications for Alnylam’s **Amvuttra** and next-generation **nucresiran**. - The FDA approved Revolution Medicines’ RAS-targeting pancreatic cancer drug, **Rasonque**, after a pivotal trial that nearly doubled median survival to **13.2 months versus 6.7 months** with chemotherapy in previously treated patients. The approval is framed as a landmark advance for pancreatic cancer and for targeting RAS proteins. - Rasonque’s approval sets a new standard of care but comes with notable caveats: the drug costs about **$39,800 per month**, has substantial skin and mouth toxicities, and patients eventually develop resistance. It may also have activity in other RAS-driven tumors such as lung and colorectal cancers. - The STAT piece summarizes these biotech developments without disclosing full technical or algorithmic details of the Moderna–Merck vaccine; readers are referred to separate reporting for deeper coverage of the vaccine’s internal algorithm and trial data.
## Clinical Analysis & Structured Key Points
[Skip to Main Content](https://www.statnews.com/2026/08/27/biotech-news-whats-in-merck-and-modernas-cancer-vaccine-algorithm/?utm_campaign=rss#wrapper) [ ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo-white.svg) ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo.svg) ](https://www.statnews.com/) * [Manage alerts for this article](https://www.statnews.com/my-account/edit/#emails) * Email this article * [Share this article](https://www.statnews.com/2026/08/27/biotech-news-whats-in-merck-and-modernas-cancer-vaccine-algorithm/?utm_campaign=rss) [Hospitals](https://www.statnews.com/category/hospitals/) [Mental Health](https://www.statnews.com/topic/mental-health/) [Cancer](https://www.statnews.com/topic/cancer/) * [Newsletters](https://www.statnews.com/signup/) * [Log In](https://www.statnews.com/login/) * [My Account](https://www.statnews.com/my-account/) * [Subscribe Now](https://www.statnews.com/stat-plus/) My Account * [Settings Complete your personal information for a more tailored experience ](https://www.statnews.com/my-account/) * [Billing](https://www.statnews.com/my-account/billing/) * [Log In](https://www.statnews.com/login/) [ ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo.svg) Reporting from the frontiers of health and medicine ](https://www.statnews.com/) * [Newsletters](https://www.statnews.com/signup/) * [Log In](https://www.statnews.com/login/) * [My Account](https://www.statnews.com/my-account/) * [Subscribe Now](https://www.statnews.com/stat-plus/) * [Biotech](https://www.statnews.com/category/biotech/) * [Pharma](https://www.statnews.com/category/pharma/) * [Public Health](https://www.statnews.com/category/health/) * [Health Tech](https://www.statnews.com/category/health-tech/) * [Policy](https://www.statnews.com/category/politics/) * [Science](https://www.statnews.com/category/in-the-lab/) * [First Opinion](https://www.statnews.com/category/first-opinion/) * [STAT+](https://www.statnews.com/topic/stat-plus/) * [STAT Events](https://www.statnews.com/events/) [ ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo.svg) ](https://www.statnews.com/) Search * [Log In](https://www.statnews.com/login/) * [Subscribe Now](https://www.statnews.com/stat-plus/) * [My Account](https://www.statnews.com/my-account/) [Home](https://www.statnews.com/) News * [Latest](https://www.statnews.com/latest/) * [Series & Investigations](https://www.statnews.com/stat-series-and-investigations-award-winning-journalism/) * Business * [Biotech](https://www.statnews.com/category/biotech/) * [Pharma](https://www.statnews.com/category/pharma/) * [Health Tech](https://www.statnews.com/category/health-tech/) * [Health Insurance](https://www.statnews.com/category/insurance/) * [Hospitals](https://www.statnews.com/category/hospitals/) * [Medical Devices](https://www.statnews.com/topic/medical-devices/) * Washington * [Policy](https://www.statnews.com/category/politics/) * [FDA](https://www.statnews.com/topic/fda/) * [NIH](https://www.statnews.com/topic/nih/) * Science * [CRISPR](https://www.statnews.com/topic/crispr/) * [Gene Therapy](https://www.statnews.com/topic/gene-therapy/) * [Neuroscience](https://www.statnews.com/topic/neuroscience/) * Public Health * [Addiction](https://www.statnews.com/topic/addiction/) * [Covid-19](https://www.statnews.com/topic/coronavirus/) * [Abortion](https://www.statnews.com/topic/abortion/) * [Health Disparities](https://www.statnews.com/topic/health-disparities/) * [Infectious Disease](https://www.statnews.com/topic/infectious-disease/) * [Mental Health](https://www.statnews.com/topic/mental-health/) * Disease * [Cancer](https://www.statnews.com/topic/cancer/) * [Cardiovascular Disease](https://www.statnews.com/topic/cardiovascular-disease/) * [Chronic Disease](https://www.statnews.com/topic/chronic-disease/) * [Diabetes](https://www.statnews.com/topic/diabetes/) * [Alzheimer's](https://www.statnews.com/topic/alzheimers/) * [Obesity](https://www.statnews.com/topic/obesity/) * Features * [Health Care Costs](https://www.statnews.com/health-insurance-costs-out-of-pocket-out-of-reach-series/) * [The Deadliest Drug](https://www.statnews.com/alcohol-epidemic-hiding-plain-sight-deadliest-drug-series/) * [Science, Shattered](https://www.statnews.com/american-science-shattered/) [Newsletters](https://www.statnews.com/signup/) [Opinion](https://www.statnews.com/category/first-opinion/) Columns * [Adam Feuerstein](https://www.statnews.com/category/adams-take/) * [Matthew Herper](https://www.statnews.com/category/matts-take/) * [Ed Silverman](https://www.statnews.com/category/pharmalot-view/) [Reports](https://reports.statnews.com/) [E-books](https://www.statnews.com/ebooks/) [Podcasts](https://www.statnews.com/podcasts/) [Tools & Trackers](https://www.statnews.com/trackers/) * [CRISPR Tracker](https://www.statnews.com/feature/crispr/tracker/) * [Breakthrough Device Tracker](https://www.statnews.com/feature/stat-plus/breakthrough-device-designation-fda-tracker/) * [Generative AI Tracker](https://www.statnews.com/feature/stat-plus/generative-ai-health-hospitals-tracker/) * [Obesity Drug Tracker](https://www.statnews.com/2023/09/12/new-weight-loss-drug-tracker-novo-nordisk-eli-lilly/) [Events](https://www.statnews.com/events/) * [Upcoming Events](https://www.statnews.com/events#upcoming-events) * [Summits](https://www.statnews.com/stat-summits/) [Community](https://www.statnews.com/community/) * [STAT Wunderkinds 2026](https://www.statnews.com/wunderkinds-nominate/) [Video](https://youtube.com/@Statnews) [Advertise](https://www.statnews.com/advertise/) * [STAT Brand Studio](https://sbs.statnews.com/) What's the word? Test your knowledge with our new weekday mini crossword [ Start solving ](https://www.statnews.com/stat-mini-crossword/) Newsletter[The Readout](https://www.statnews.com/category/readout-newsletter/) # What’s in Merck and Moderna’s cancer vaccine algorithm? ## A heart drug failure, RevMed’s pancreatic cancer drug approved, and more biotech news from The Readout * [Manage alerts for this article](https://www.statnews.com/my-account/edit/#emails) * Email this article * [Share this article](https://www.statnews.com/2026/08/27/biotech-news-whats-in-merck-and-modernas-cancer-vaccine-algorithm/?utm_campaign=rss) ![A strand of mRNA replicating itself 6 times.](https://www.statnews.com/wp-content/uploads/2022/11/5-645x645.jpg) Christine Kao/STAT ![](https://www.statnews.com/wp-content/uploads/2021/02/meghana-k-avatar-small2-80x80.png) By [Meghana Keshavan](https://www.statnews.com/staff/meghana-keshavan/) Aug. 27, 2026 Biotech Correspondent ![](https://www.statnews.com/wp-content/uploads/2021/02/meghana-k-avatar-small2-80x80.png) [Meghana Keshavan](https://www.statnews.com/staff/meghana-keshavan/) 1. [](https://x.com/megkesh "X") meghana.keshavan@statnews.com Meghana Keshavan covers biotech and contributes to [The Readout newsletter](https://www.statnews.com/signup/readout/). [Subscribe](https://www.statnews.com/stat-plus/) or [log in](https://www.statnews.com/login/) to STAT+ to unlock email alerts _Want to stay on top of the science and politics driving biotech today?[Sign up](https://www.statnews.com/signup/readout/) to get our biotech newsletter in your inbox._ Today, we look at how a China biotech crackdown could benefit Europe, what a rival drug failure might mean for Alnylam, the algorithm behind the Moderna-Merck cancer vaccine, and a landmark approval in pancreatic cancer. Advertisement RIP, Tim Curry. I shall mourn how humbly you buttle. ## The need-to-know this morning * **Moderna** is [raising $2 billion](https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/moderna-announces-proposed-private-placement-of-2.0-billion-of-conver-1213089) in convertible debt. The new financing comes one week after the Phase 3 success of its personalized cancer vaccine. ## The power of the Moderna-Merck cancer vaccine may hinge on an algorithm Moderna and Merck’s [personalized cancer vaccine](https://www.statnews.com/2026/08/24/inside-moderna-and-merck-cancer-vaccine-triumph/) could become the first approved medicine whose genetic instructions are essentially written by an algorithm. For each patient, software analyzes thousands of tumor mutations and chooses 34 neoantigens to encode into a bespoke mRNA vaccine — a regulatory and computational experiment that some researchers now believe could be the treatment’s “secret sauce.” That said, some skeptical Wall Street investors think that perhaps the personalization isn’t necessary at all, and that mRNA itself primes tumors to respond better to Keytruda. So what’s in that algorithm? Advertisement “I have no idea,” said Alex Rubinsteyn, a cancer vaccine expert at the University of North Carolina. “Everyone claims what they have is proprietary intelligence.” [Read more](https://www.statnews.com/2026/08/27/moderna-merck-cancer-vaccine-secret-ingredient-an-algorithm/). ## U.S. crackdown on Chinese biotech could benefit Europe A bipartisan bill aimed at limiting U.S. biotech ties with China could end up handing Europe a competitive advantage, executives from the Croatia-based CRO Optimapharm opine for STAT. The proposed Biotech Investment National Security Act, or BINSA, would broaden federal oversight of U.S. investment and dealmaking with Chinese biotech companies. However, Optimapharm’s argue, companies could simply route the drugs discovered in China through European sponsors — a strategy dubbed “Eurowashing.” This potentially could shift licensing profits, tax revenue, and clinical development activity away from the U.S. Also, biotechs often default to crowded U.S., Australian, and Western European trial sites rather than considering faster and cheaper alternatives in Central and Eastern Europe. Whether BINSA passes or not, the executives say, companies should diversify their clinical trial strategies now before geopolitical tensions make those decisions for them. [Read more.](https://www.statnews.com/2026/08/27/binsa-biotech-china-eurowashing-geography-clinical-trials/) ## A heart drug failure casts shadow over Alnylam The European Society of Cardiology Congress in Munich could offer crucial clues about the future of Alnylam’s ATTR-CM franchise, STAT’s Adam Feuerstein writes. AstraZeneca and Ionis will reveal details on why their rival gene-silencing drug, eplontersen, failed a pivotal Phase 3 study. The drug showed no cardiovascular benefit when added to widely used stabilizer drugs — which suggests that injectable gene silencers may not add much benefit to much to easier-to-use oral treatments. This will matter for Alnylam’s blockbuster, Amvuttra, and especially next-generation nucresiran, now in Phase 3 testing. Alnylam says nucresiran’s greater potency and differently designed trial can succeed where eplontersen stumbled, but investors aren’t entirely convinced. [Read more.](https://www.statnews.com/2026/08/27/alnylam-amvuttra-nucresiran-heart-drugs-esc/) ## FDA approves landmark pancreatic cancer drug The FDA has approved the buzzy pancreatic cancer drug made by Revolution Medicines. Rasonque is the first treatment to attack a genetic driver of pancreatic cancer — and what oncologists are calling the disease’s biggest therapeutic advance in decades. Advertisement In a pivotal trial, the RAS-targeting drug nearly doubled median survival to 13.2 months from 6.7 months with chemotherapy in previously treated patients. This establishes a new standard of care for a cancer with a dismal 8% five-year survival rate. The approval also caps a decades-long effort to drug the once-considered “undruggable” RAS proteins and transforms Revolution into a leader in targeted cancer medicines. The drug will cost $39,800 per month and carries substantial skin and mouth toxicities, and patients eventually develop resistance. But it could potentially have benefits in other RAS-driven tumors, including lung and colorectal cancers. [Read more.](https://www.statnews.com/2026/08/26/pancreatic-cancer-drug-rasonque-approved/) ## More reads * Akeso CEO looks beyond lung cancer with biliary tract win, counters ivonescimab debate, [FiercePharma](https://www.fiercepharma.com/pharma/akeso-ceo-looks-beyond-lung-cancer-phase-3-biliary-tract-win-counters-ivonescimab-debate) * JATT mastermind launches latest biotech-focused SPAC via $60 million IPO, [FierceBiotech](https://www.fiercebiotech.com/biotech/jatt-mastermind-launches-latest-biotech-focused-spac-60m-ipo) * Biohaven strikes $795M deal for commercial partner in epilepsy, [Endpoints](https://endpoints.news/biohaven-strikes-795m-deal-for-commercial-partner-in-epilepsy/) [biotechnology](https://www.statnews.com/topic/biotechnology/), [drug development](https://www.statnews.com/topic/drug-development/), [Drug prices](https://www.statnews.com/topic/drug-prices/), [research](https://www.statnews.com/topic/research/) [Submit a correction request](https://www.statnews.com/contact/?how_can_we_help_=Editorial%20Correction%20Request)[Reprints](https://www.parsintl.com/publications/stat/) 1. ![](https://www.statnews.com/wp-content/uploads/2021/02/meghana-k-avatar-small2-80x80.png) [Meghana Keshavan](https://www.statnews.com/staff/meghana-keshavan/) 1. [](https://x.com/megkesh "X") 2. Biotech Correspondent 1. [](https://x.com/megkesh "X") 2. Meghana Keshavan covers biotech and contributes to [The Readout newsletter](https://www.statnews.com/signup/readout/). ![](https://www.statnews.com/wp-content/themes/stat/images/article-new/envelope-open.svg) ![](https://www.statnews.com/wp-content/uploads/2023/06/The-Readout-Logo-Black-640x99.png) ### Newsletter Your morning rundown of the science, politics, and money driving biotech today Please enter a valid email address. Sign Up Your data will be processed in accordance with our [Privacy Policy](https://www.statnews.com/privacy/) and [Terms of Service](https://www.statnews.com/terms-conditions/). You may opt out of receiving STAT communications at any time. Advertisement Most Popular 1. ![](https://www.statnews.com/wp-content/uploads/2026/08/AdobeStock_180917809-80x80.jpeg) [Nurse practitioner trainees find themselves stymied by shortage of clinical mentors](https://www.statnews.com/2026/08/24/nurse-practitioner-preceptor-shortage-clinical-placement-challenges/) 2. ![](https://www.statnews.com/wp-content/uploads/2026/08/daniel-80x80.jpg) [Hospitals are plotting a long-shot push to roll back $1 trillion in Medicaid cuts](https://www.statnews.com/2026/08/27/hospitals-lobby-reverse-medicaid-cuts-part-2-unraveled-series/) 3. ![](https://www.statnews.com/wp-content/uploads/2026/08/AdobeStock_998225050-80x80.jpeg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [The mystery of Moderna’s magic algorithm](https://www.statnews.com/2026/08/27/moderna-merck-cancer-vaccine-secret-ingredient-an-algorithm/) 4. ![](https://www.statnews.com/wp-content/uploads/2026/08/Bolner01-80x80.jpg) [A state gave sheriffs 20% of its opioid settlement cash. We followed the money](https://www.statnews.com/2026/08/27/opioid-settlement-funds-enforcement-or-treatment-louisiana-sheriff-investigation/) 5. ![](https://www.statnews.com/wp-content/uploads/2026/08/AdobeStock_1853561084_Editorial_Use_Only-80x80.jpeg) [I studied Reddit forums on menopause — and found what doctors are missing](https://www.statnews.com/2026/08/27/menopause-perimenopause-symptoms-reddit-clinical-data-study/) #### [ Reports ](https://reports.statnews.com/) [ ![](https://www.statnews.com/wp-content/uploads/2026/08/2026_CancerReport_ReportCover-328x424.jpg) Explore Cancer’s transformational moments: KRAS, CAR-T, immunotherapy, and more ](https://reports.statnews.com/products/cancer-transformational-moments-advances-in-kras-car-t-immunotherapy) Advertisement #### [Events](https://www.statnews.com/events/) [ ![](https://www.statnews.com/wp-content/uploads/2026/07/924_Samsung_VirtualEvent_Wordpress_FeaturedImage-80x80.jpg) Biosimilars: Have We Reached an Inflection Point? Virtual Sep 24 ](https://www.statnews.com/event/biosimilars-what-is-next-virtual-event-sept-2026/) [ ![](https://www.statnews.com/wp-content/uploads/2026/01/Flagship2026_Wordpress_CalendarImageRegGoLive-1-80x80.jpg) 2026 STAT Summit Boston, MA Oct 14 ](https://www.statnews.com/event/2026-stat-summit/) [ ![](https://www.statnews.com/wp-content/uploads/2026/07/2026_DD_OfficeHours_VirtualEvent_Wordpress_CalendarImage-80x80.jpg) Office Hours with Isabella Cueto and Lev Facher Virtual Jul 29 ](https://www.statnews.com/event/deadliest-drug-series-office-hours-ama-july-2026/) Most Read in [STAT+](https://www.statnews.com/stat-plus/) 1. ![](https://www.statnews.com/wp-content/uploads/2026/08/image-15-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Inside Moderna and Merck’s cancer vaccine triumph](https://www.statnews.com/2026/08/24/inside-moderna-and-merck-cancer-vaccine-triumph/) 2. ![](https://www.statnews.com/wp-content/uploads/2026/08/Revmed_campus2-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [FDA approves new pancreatic cancer drug expected to usher in new era of treatment](https://www.statnews.com/2026/08/26/pancreatic-cancer-drug-rasonque-approved/) 3. ![](https://www.statnews.com/wp-content/uploads/2026/08/AP26111614763455-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [HHS document offers new clues to Kennedy’s vaccine plans](https://www.statnews.com/2026/08/21/rfi-reveals-possible-kennedy-strategy-vaccine-policy-changes/) 4. ![](https://www.statnews.com/wp-content/uploads/2020/02/AdobeStock_284333299-80x80.jpeg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Moderna and Merck say mRNA cancer vaccine succeeded in late-stage melanoma trial](https://www.statnews.com/2026/08/19/mrna-cancer-vaccine-trial-melanoma-merck-moderna/) 5. ![](https://www.statnews.com/wp-content/uploads/2026/08/LongLab_Immunofluorescence-of-the-biosynthetic-enzyme-for-exercise-inducible-Lac-Phe-Cndp2-green-and-nuclei-DAPI-blue-in-mouse-gut-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [A pill that mimics exercise? Early results on drug designed to maintain both weight loss and muscle mass](https://www.statnews.com/2026/08/18/enveda-pill-mimics-exercise-phase-one-trial-leptin-weight-loss-maintenance/) #### Recommended ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) D.C. Diagnosis D.C. Diagnosis August 27, 2026 ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: Hospitals plot their response to funding cuts ](https://www.statnews.com/2026/08/27/hospitals-lobby-medicaid-cuts-rasonque-approved-dc-diagnosis/) By [John Wilkerson](https://www.statnews.com/staff/john-wilkerson/) ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) Adam's Biotech Scorecard Adam's Biotech Scorecard August 27, 2026 ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: Alnylam’s heart drug troubles take center stage at a cardiology conference ](https://www.statnews.com/2026/08/27/alnylam-amvuttra-nucresiran-heart-drugs-esc/) By [Adam Feuerstein](https://www.statnews.com/staff/adam-feuerstein/) Advertisement ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) Biotech Biotech August 27, 2026 ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: The mystery of Moderna’s magic algorithm
## Related Clinical Research

- [Massachusetts hospital CEOs saw large pay increases in 2024, Mass General Brigham CEO tops list](https://medichelpline.com/clinical-feed/stat-news-2-stat-leaders-of-mass-general-dana-farber-among-hospital-execs-who-got-big.md)
- [Enveda’s ENV-308: Early Phase 1 data on a pill that aims to mimic exercise and preserve lean mass](https://medichelpline.com/clinical-feed/stat-news-0-stat-a-pill-that-mimics-exercise-early-results-on-drug-designed-to-maintain.md)
- [Link Between Daily Sugary Drink Consumption and Increased Stomach Cancer Risk](https://medichelpline.com/clinical-feed/medical-news-today-1-daily-sugary-drink-consumption-linked-to-more-than-double-stomach-cancer-risk.md)
- [Waist circumference predicts mortality more than BMI in adults 65+: study findings](https://medichelpline.com/clinical-feed/medical-news-today-0-bmi-vs-waist-size-study-finds-belly-fat-matters-more-than-weight-for-death-risk.md)
- [Cardiac-targeted delivery strategies for advanced therapies in heart disease](https://medichelpline.com/clinical-feed/pubmed-42284133.md) (DOI: 10.1093/eurheartj/ehag432)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.